Novel IDO Inhibitors and Methods of Use Thereof

Abstract

Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.

1 . (canceled) 
     
     
         2 . A compound having indoleamine 2,3 dioxygenase (IDO) inhibitory activity, said compound having the formula of: 
       
         
           
           
               
               
           
         
         wherein X 1 , X 2 , X 3 , X 4 , X 11 , X 12 , X 13 , and X 14  are independently selected from the group consisting of halide, H, OH, R, OR, NHR, and SR, and wherein R is selected from the group consisting of an alkyl group, cyclic alkyl group, and aryl group. 
       
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . A pharmaceutical composition for the treatment of cancer comprising a pharmaceutically acceptable carrier and an effective amount at least one indoleamine 2,3-dioxygenase (IDO) inhibitor, wherein at least one of said IDO inhibitors is the compound of  claim 2 . 
     
     
         6 - 16 . (canceled) 
     
     
         17 . The pharmaceutical composition of  claim 5 , further comprising at least one signal transduction inhibitor (STI). 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . The pharmaceutical composition of  claim 5 , further comprising at least one chemotherapeutic agent. 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . The pharmaceutical composition of  claim 20 , wherein said at least one chemotherapeutic agent is selected from the group consisting of paclitaxel (Taxol®), cisplatin, docetaxol, carboplatin, vincristine, vinblastine, methotrexate, cyclophosphamide, CPT-11, 5-fluorouracil (5-FU), gemcitabine, estramustine, carmustine, adriamycin (doxorubicin), etoposide, arsenic trioxide, irinotecan, and epothilone derivatives. 
     
     
         24 .- 34 . (canceled) 
     
     
         35 . A compound which is the hydroquinone form of the compound of  claim 2 . 
     
     
         36 . (canceled) 
     
     
         37 . The compound of  claim 2 , wherein X 1 , X 2 , X 3 , X 4 , X 12 , X 13 , and X 14  are H. 
     
     
         38 . The compound of  claim 2 , wherein X 11  is R. 
     
     
         39 . The compound of  claim 38 , wherein R is aryl. 
     
     
         40 . The compound of  claim 37 , wherein X 11  is R. 
     
     
         41 . The compound of  claim 39 , wherein R is aryl.